Firefly Neuroscience (AIFF)
FDA-cleared EEG assessment systems and brain-function reports for clinicians and drug developers.
$1.14
vs last close−0.06 (−4.98%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Cost of revenue | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 1 | −1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 2 | 1 | 1 | 3 | 3 | 2 | 2 | 3 | 2 | 2 | 2 | |
| Research & development | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 0 | 2 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |
| Selling & marketing | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 0 | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −1 | −2 | −1 | 0 | −4 | −3 | −2 | −2 | −3 | −2 | −2 | −2 |
| 0 | 0 | 0 | 0 | 0 | 0 | −11 | 0 | 0 | 0 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | −1 | 11 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −1 | −1 | −1 | 0 | −4 | −4 | −13 | −2 | −3 | −2 | −2 | −2 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −1 | −1 | −1 | 0 | −4 | −4 | −13 | −2 | −3 | −2 | −2 | −2 |
| Net income | −1 | −1 | −1 | 0 | −4 | −4 | −13 | −2 | −3 | −2 | −2 | −2 |
| EPS, basic | −$0.08 | −$0.14 | −$0.09 | −$0.05 | −$0.61 | −$0.45 | −$1.74 | −$0.14 | −$0.20 | −$0.21 | −$0.13 | −$0.10 |
| EPS, diluted | −$0.08 | −$0.14 | −$0.09 | −$0.05 | −$0.61 | −$0.45 | −$1.74 | −$0.14 | −$0.20 | −$0.20 | −$0.13 | −$0.10 |
| Weighted average shares, basic | 8 | 8 | 8 | 8 | 7 | 8 | 10 | 13 | 13 | 13 | 16 | 21 |
| Weighted average shares, diluted | 8 | 8 | 8 | 8 | 7 | 8 | 10 | 13 | 13 | 13 | 16 | 21 |
| EBITDA | −1 | −1 | −1 | 0 | −4 | −3 | −13 | −2 | −2 | −3 | −2 | −2 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −1 | −1 | −1 | 0 | −4 | −3 | −13 | −2 | −3 | −3 | −2 | −2 |
